Profile data is unavailable for this security.
About the company
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
- Revenue in ILS (TTM)1.72m
- Net income in ILS-27.10m
- Incorporated1994
- Employees5.00
- LocationCan Fite Biopharma Ltd10 Bareket Street, Kiryat Matalon,P.O. Box 7537PETAH TIKVA 49170IsraelISR
- Phone+972 39241114
- Fax+972 39249378
- Websitehttps://www.canfite.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals Inc | 4.17m | -26.11m | 16.06m | 3.00 | -- | -- | -- | 3.85 | -23.04 | -23.04 | 2.93 | 4.32 | 0.1919 | 1.59 | 2.71 | 451,383.30 | -113.08 | -- | -148.26 | -- | 42.47 | -- | -589.17 | -- | 2.63 | -44.07 | 0.0342 | -- | 168.70 | -- | -111.48 | -- | -- | -- |
| Zelira Therapeutics Ltd | 1.44k | -7.91m | 16.08m | 8.00 | -- | -- | -- | 11,176.12 | -0.3172 | -0.3172 | 0.00006 | -0.3749 | 0.0002 | 0.0102 | 0.003 | -- | -118.74 | -50.35 | -- | -56.97 | -1,236.36 | 43.05 | -583,283.30 | -2,379.12 | 0.0244 | -6.50 | -- | -- | -99.30 | -77.07 | 90.08 | -- | -- | -- |
| Kane Biotech Inc | 1.31m | -4.43m | 16.51m | -- | -- | -- | -- | 12.64 | -0.0114 | -0.0214 | 0.0034 | -0.0047 | 0.173 | 1.30 | 2.42 | -- | -58.59 | -80.66 | -192.03 | -- | -16.60 | 44.47 | -338.70 | -257.96 | 0.7172 | -10.81 | 1.53 | -- | 1,296.75 | 4.21 | 30.71 | -- | -1.53 | -- |
| Can Fite Biopharma Ltd | 1.72m | -27.10m | 17.56m | 5.00 | -- | 0.6814 | -- | 10.18 | -26.86 | -26.86 | 1.87 | 9.84 | 0.0821 | -- | -- | 344,915.20 | -129.00 | -91.42 | -184.56 | -113.40 | -- | -- | -1,571.25 | -1,372.50 | -- | -- | 0.00 | -- | -9.29 | -19.81 | -3.22 | -- | 10.76 | -- |
| Mangalam Drugs and Organics Ltd | 81.08m | -10.52m | 17.91m | 414.00 | -- | -- | -- | 0.2209 | -19.53 | -19.53 | 150.57 | -- | -- | -- | -- | 5,758,911.00 | -- | 2.90 | -- | 5.34 | 39.15 | 29.02 | -12.97 | 2.46 | -- | -0.9827 | -- | -- | -13.66 | 2.42 | 174.27 | -4.02 | 23.85 | -- |
| Sunshine Biopharma Inc | 114.98m | -18.46m | 18.14m | 52.00 | -- | 0.226 | -- | 0.1577 | -2.03 | -2.03 | 10.74 | 5.31 | 1.21 | 2.09 | 10.12 | 717,764.30 | -19.47 | -68.65 | -23.80 | -89.02 | 33.01 | 32.79 | -16.06 | -81.12 | 2.09 | -209.95 | 0.00 | -- | 44.75 | 340.11 | -13.94 | -- | 370.33 | -- |
| ExpreS2ion Biotech Holding AB | 3.76m | -15.66m | 19.36m | 20.00 | -- | 1.26 | -- | 5.15 | -44.22 | -44.22 | 5.14 | 12.52 | 0.1305 | -- | 5.67 | 571,157.90 | -54.33 | -58.63 | -85.25 | -70.70 | 55.64 | -18.17 | -416.26 | -621.40 | -- | -- | 0.0433 | -- | -11.07 | -10.76 | 60.57 | -- | 5.08 | -- |
Data as of Feb 11 2026. Currency figures normalised to Can Fite Biopharma Ltd's reporting currency: Israeli Shekel ILS
